Cell-free DNA ultra-low-pass whole genome sequencing distinguishes malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion - Szymanski, Jeffrey J.; Sundby, R. Taylor; Jones, Paul A.; Srihari, Divya; Earland, Noah; Harris, Peter K.; Feng, Wenjia; Qaium, Faridi; Lei, Haiyan; Roberts, David; Landeau, Michele; Bell, Jamie; et al. (medRxiv, 2021)
Background The leading cause of mortality for patients with the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome is development of Malignant Peripheral Nerve Sheath Tumor (MPNST), an aggressive soft tissue sarcoma. In the setting of NF1, this cancer type frequently arises from within its common and benign precursor, plexiform neurofibroma (PN). Transformation from the benign PN to MPNST is challenging to diagnose due to difficulties in distinguishing cross-sectional imaging results and intralesional heterogeneity resulting in biopsy sampling errors.Methods and Findings This multi-institutional study used ultra-low-pass whole genome sequencing (ULP-WGS) of plasma cell-free DNA (cfDNA) to distinguish between MPNST and PN in patients with NF1. Using copy number to estimate the fraction of plasma cfDNA originating from tumor (tumor fraction), we developed a noninvasive classifier which differentiates MPNST from PN with 91% specificity. Healthy controls without NF1 (subjects = 14, plasma samples= 14), PN (subjects = 45, plasma samples = 45), and MPNST (subjects = 14, plasma samples = 48) cohorts showed significant differences in tumor fraction in plasma (P = 0.006) as well as cfDNA fragment length (P < 0.001) with MPNST samples harboring shorter fragments and being enriched for tumor-derived cfDNA relative to PN and healthy controls. Mutational analysis demonstrated focal NF1 copy number loss in PN and MPNST patient plasma but not in healthy controls. Genomic alterations associated with malignant transformation (focal copy number gains in chromosome 8 and copy number losses in SUZ12, SMARCA2, CDKN2A/B, and chromosome arm 9p) were more prominently observed in MPNST plasma. Furthermore, the sum of longest tumor diameters (SLD) visualized by cross-sectional imaging correlated significantly with paired tumor fractions in plasma from MPNST patients (ρ = 0.50, P = 0.0007). On case series analysis, tumor fraction levels in plasma correlated with treatment response to therapy and minimal residual disease (MRD) detection before relapse.Conclusions Tumor fraction levels derived from copy number alteration analysis of plasma cfDNA using ULP-WGS significantly correlated with MPNST tumor burden, distinguished MPNST from its benign PN precursor, and correlated with treatment response. In the future, our findings could form the basis for improved early cancer detection and monitoring in high-risk cancer-predisposed populations.Competing Interest StatementA.A.C. has patent filings related to cancer biomarkers. A.A.C. has served as a consultant/advisor to Roche, Tempus, Geneoscopy, Fenix Group International, and Guidepoint. A.A.C. has stocked options in Geneoscopy. No potential conflicts of interest were disclosed by the other authors.Funding StatementThis work was supported by grants from the Childrens Cancer Foundation NextGen Award (R.T.S.), the National Institute of General Medical Sciences (5T32GM007067 supporting P.A.J.), the Center for Cancer Research Flex Award (J.F.S), the NCI Center for Cancer Research Intramural Research Program (1ZIABC011722-04 supporting R.T.S, J.F.S. and 1ZIABC010801-13 B.C.W.), the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research (A.C.H.), National Cancer Institute (1K08CA238711 to A.A.C.), the Cancer Research Young Investigator Award (A.A.C.), and the V Foundation for Cancer Research (A.A.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NCI protocol NCT01109394, NIH Intramural IRB identifier 10C0086; NCI protocol NCT00924196, NIH Intramural IRB identifier 08C0079; WUSTL protocol NCT04354064, Washington University in St. Louis School of Medicine Human Research Protection Office IRB identifiers 201903142 and 201203042All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be publicly available following print publication of the study. https://doi.org/10.7303/syn23651229 ANatypical neurofibromaCNAcopy number alterationcfDNAcell-free DNANCINational Cancer InstituteNF1neurofibromatosis type 1PNplexiform neurofibromaMPNSTmalignant peripheral nerve sheath tumorROCreceiver operating characteristicSLDsum of longest diametersULP-WGSultra-low-pass whole genome sequencingWUSTLWashington University in Saint Louis.